Glomerulonephritis Clinical Trials

31 recruitingLast updated: June 18, 2026

There are 31 actively recruiting glomerulonephritis clinical trials across 36 countries. Studies span Phase 2, Phase 3, Early Phase 1, Not Applicable, Phase 4. Top locations include New York, New York, United States, Paris, France, Beijing, China. Updated daily from ClinicalTrials.gov.


Glomerulonephritis Trials at a Glance

31 actively recruiting trials for glomerulonephritis are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 2 with 12 trials, with the heaviest enrollment activity in New York, Paris, and Beijing. Lead sponsors running glomerulonephritis studies include Novartis Pharmaceuticals, Mayo Clinic, and Alexandria University.

Browse glomerulonephritis trials by phase

Treatments under study

About Glomerulonephritis Clinical Trials

Looking for clinical trials for Glomerulonephritis? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glomerulonephritis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glomerulonephritis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 31 trials

Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled71 locationsNCT06500702
Recruiting
Phase 2

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

Kidney DiseasesImmune System DiseasesAutoimmune Diseases+3 more
University of Leicester24 enrolled6 locationsNCT04663204
Recruiting
Phase 3

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Kidney DiseasesKidney Diseases, ChronicUrological Diseases+5 more
Novartis Pharmaceuticals220 enrolled18 locationsNCT06858319
Recruiting

Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.

IGA Glomerulonephritis
Chinese PLA General Hospital30 enrolled1 locationNCT07585981
Recruiting
Phase 2

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Glomerulonephritis, IGAImmunoglobulin A Nephropathy
Novartis Pharmaceuticals20 enrolled18 locationsNCT06797518
Recruiting
Phase 2

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Fibrillary Glomerulonephritis
Mayo Clinic20 enrolled1 locationNCT06295770
Recruiting
Phase 3

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals225 enrolled50 locationsNCT03955445
Recruiting
Not Applicable

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

HealthyAtypical Hemolytic Uremic SyndromeMembranoproliferative Glomerulonephritis+1 more
Mario Negri Institute for Pharmacological Research105 enrolled1 locationNCT05996731
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499
Recruiting

The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.

Chronic Kidney DiseaseChronic Glomerulonephritis
Zhujiang Hospital2,900 enrolled2 locationsNCT07330362
Recruiting
Phase 2

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Glomerulonephritis Rapidly Progressive
Alentis Therapeutics AG80 enrolled49 locationsNCT06047171
Recruiting
Early Phase 1

A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

SLEANCA-associated VasculitisIIM+5 more
Nanjing Bioheng Biotech Co., Ltd.84 enrolled1 locationNCT07203404
Recruiting
Phase 2

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

Proliferative Glomerulonephritis With Monoclonal IgG Deposits
Mayo Clinic40 enrolled4 locationsNCT05654506
Recruiting
Phase 4

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

IgA NephropathyRenal Insufficiency, ChronicIgA Vasculitis+1 more
Christian Medical College, Vellore, India585 enrolled12 locationsNCT06676384
Recruiting
Phase 2

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 GlomerulopathyIdiopathic Immune Complex-Mediated Glomerulonephritis
Omeros Corporation20 enrolled6 locationsNCT06209736
Recruiting
Phase 2

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

C3 GlomerulopathyDense Deposit DiseaseMembranoproliferative Glomerulonephritis+2 more
Region Skane30 enrolled4 locationsNCT04183101
Recruiting
Phase 3

A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial

ANCA-associated VasculitisCrescentic GlomerulonephritisRapidly Progressive Glomerulonephritis
Assistance Publique - Hôpitaux de Paris126 enrolled24 locationsNCT05946564
Recruiting

AI scribe for clinical documentation

paediatric respiratory conditions e.g. asthmapaediatric neurological conditions including seizuresfailure to thrive.+2 more
Queensland Children's Hospital150 enrolled1 locationACTRN12625000432415
Recruiting

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

Kidney DiseasesDiabetic NephropathyKidney Failure, Chronic+2 more
The Rogosin Institute2,000 enrolled1 locationNCT01802034